Our Work
At Orphalan we identify, develop and provide access to innovative treatments for patients with rare diseases.
In Rare Diseases
A disease is rare when it affects fewer than 1 in 2,000 people. There are more than 7,000 known rare diseases. The lack of information about these diseases can often lead to delayed diagnosis and further complications as a result. Many diseases have inadequate or no treatment options; where treatments do exist, access to them can be patchy. We need more research, better therapies, and a global network to ensure that experts, researchers, clinicians and patient communities are connected.
Around the world, 300 million people suffer with a rare disease.
At Orphalan we work with partners to develop and deliver innovative treatments for patients living with rare diseases. Our first commercialized product is for Wilson disease, a rare genetic condition affecting 1 in 30,000 people globally.
Wilson Disease
What is Wilson disease?
Wilson disease is a rare genetic disorder that impairs the body’s ability to remove copper. Copper, an essential mineral, is naturally occurring in many foods and contributes to the proper performance of metabolic processes throughout the body. A normal diet contains more copper than the body needs, and the majority of excess dietary copper is excreted in the bile via the liver, or through other gastrointestinal secretions.
Individuals affected by Wilson disease are unable to eliminate this excess copper properly; without appropriate treatment, copper builds up in the tissues and organs, including the liver and brain, resulting in a range of potentially severe liver, neurological and psychiatric symptoms. Though Wilson disease is present at birth, these symptoms will not appear until the copper begins to accumulate.
What causes Wilson disease?
Wilson disease is caused by a mutation in the ATP7B gene on chromosome 13. This mutation prevents liver cells from being able to process and remove excess copper into the bile. The excess copper accumulates in the liver, followed by other body organs, gradually damaging them.
Copper deposits may accumulate across different parts of the body, including the liver, brain, eyes, and other organs and can lead to a wide range of signs and symptoms. Wilson disease thus affects each person differently; some of the main signs and symptoms are outlined below:
Hepatic
Scarring of the liver (cirrhosis) which prevents normal functioning. Liver failure can occur slowly over years (chronic), or suddenly (acute).
Neurologic
Tremors, speech difficulties, migraine headaches, insomnia, and even seizures can occur
Psychiatric
Psychiatric symptoms might include depression and personality changes.
Other
The kidneys and bones can also be affected in Wilson Disease, potentially causing kidney stones or arthritis, respectively. Dark rings around the iris (colored part) of the eye or cataracts may occur in some people.
Please note, this is not a comprehensive list of symptoms associated with Wilson Disease.
How is Wilson Disease Treated?
All patients with a confirmed diagnosis of Wilson disease should be started on lifelong medical therapy combined initially with a low copper diet. Wilson disease medications need to be taken daily, and dosing should be administered consistently and spaced out between meals to achieve full efficacy. Failure to comply with lifelong therapy can lead to recurrent or new symptoms and eventually disease progression.
Medications work by either blocking copper absorption (zinc therapy) or by binding to free copper (chelating agents such as trientine). Patients who adhere to their prescribed regime and take their medicines regularly are able to manage their disease effectively and maintain acceptable levels of copper to live full, independent lives.
With Patients
Orphalan recognizes the outstanding efforts of the many organizations that have dedicated themselves to improving the awareness of Wilson disease and providing support to patients with Wilson disease.
The following organizations provide important educational resources and support services for the Wilson disease community, as well as information about other rare diseases.
Patient Associations
United States
Wilson Disease Association
224 W 35th Street Ste 500
#676
New York, NY 10001
Phone: (00) 1-866-961-0533
Email: info@wilsondisease.org
Website: www.wilsonsdisease.org
Bulgaria
Bulgarian Association Wilson Disease (BAWD)
Email: info@wilsonbg.org
Website: www.wilsonbg.org
Denmark
Danish Wilson Disease Patient Association
Wilsonpatientføreningen
Email: info@Wilson.dk
Website: www.wilsons.dk
Finland
The Finnish Movement Disorders Association – Wilson’s Disease section
Website: www.liikehairio.fi
France
Bernard Pepin Association for Wilson Disease in France
Association Bernard Pepin pour la Maladie de Wilson
Hopital Fondation Adolphe de Rothschild
29 rue Manin 75019 Paris
Wesbite:
www.abpmaladiewislon.fr
National Reference center for Wilson Disease in France
Centre National de Référence Wilson
Hopital Fondation Adolphe de Rothschild
29 rue Manin 75019 Paris
Email : crmr.wilson@for.paris
Wesbite : www.cmrwilson.com
Germany
Morbus Wilson e.V.
Geschäftsstelle
Zehlendorfer Damm 119
14532 Kleinmachnow
Tel.: +49 30 80 49 84 86
Email: info@morbus-wilson.de
Website: www.morbus-wilson.de
Italy
Associazione Nazionale Malattia di Wilson
Email: info@malattiadiwilson.it
Website: www.malattiadiwilson.it
Netherlands
Dutch Wilson Disease Association
Phone: (033) 46 12 231
Email: info@leverpatientenvereniging.nl
Website: www.leverpatientenvereniging.nl
Poland
Polish Patients’ Society
Website: www.zyciezchorobawilsona.pl
Romania
Wilson Disease Association Romania
Website: www.wda-romania.org
Serbia
Humanity Assocation Wilson, Humanitamo Udruženje
Email: office@wilson.org.rs
Website: www.wilson.org.rs
Spain
Asociación Española de Familiares y Enfermos de Wilson (AEFE)
C/Molineta, 1
C.P. 04230 – Huércal de Almería
Phone: +34 634 58 26 80
Email: asociaciondewilson@gmail.com
Website: www.enfermedaddewilson.org
Switzerland
Wilsonföreningen
Online contact form: www.wilsonforeningen.se
Website: www.wilsonforeningen.se
United Kingdom
Wilson’s Disease Support Group UK (WDSG-UK)
Email addresses available at: www.wilsonsdisease.org.uk/Site/Pages/Contacts
Website: www.wilsonsdisease.org.uk
Rare Disease Organisations
1779 Massachusetts Avenue
Suite 500
Washington, DC 20036
Phone: (202) 588-5700
Online contact form: www.rarediseases.org/about/contact-us
Website: www.rarediseases.org
Our Work With the Medical Community
At Orphalan, we continuously engage with healthcare professionals and patient advocacy groups in our common goal of improving care and services for patients with rare disease. Together, by taking a patient-centric approach, in partnership with healthcare professionals, our mission is to collaborate to advance knowledge in rare disease and in particular to identify and find innovative solutions for the unmet needs of patients. Orphalan along with our network of top Key Opinion Leaders strive to design meaningful and important studies to improve patient care and outcomes. It is through close collaborations with healthcare professionals and scientists, that Orphalan is able to address these unmet needs of patients with rare disease and potentially transform their lives through discovery and innovation.
Investigator Initiated Research (IIR)
As part of our commitment to delivering innovative therapies to patients, Orphalan believes and values in the need to support ethically conducted independent clinical research by qualified third-party investigators.
Orphalan views scientific research produced by third party sponsors as complementary to Orphalan-sponsored research. Investigator initiated research (IIR) are studies with scientific and medical merit developed and sponsored by an independent investigator aligned with Orphalan’s areas of interest or scientific priorities. These priorities are to help Orphalan to better understand the benefit/risk profile of our therapies, as well as enabling us to explore new opportunities addressing unmet medical needs.
An IIR may be a clinical study conducted without the participation of Orphalan, for which the IIR sponsor requests Orphalan to provide either funding, drug product or both.
Areas of interest
Orphalan supports research projects related to our therapeutic products, diagnostic tests and disease of interest and that are aligned with our R&D programs.
For more information, please contact us.
Unrestricted educational grants / donations
Orphalan is committed to work in partnership with Healthcare Organisations (HCOs) and Patient Associations and Charities. We consider grant requests and donations that would benefit these organisations and their patients.
For more information, please contact us.
Wilson Disease Registry
The International Wilson Disease (iWD) Registry was established in 2021 to describe the natural history of treated Wilson Disease. With more than 340 patients enrolled by January 2024, from participating centres in the UK, France, Belgium, Spain, Germany, Poland and Saudi Arabia, the Registry is generating a wealth of data designed to identify unmet needs of patients and research priorities. Orphalan sponsors the Registry.
Find out more
Our Research
We believe that patients across the world, with a rare disease, should have access to innovative treatment that improves their care and positively impacts their lives and those of their loved ones.